Technical Data
M2750-11A
MCP2, Recombinant, Human (Macrophage/Monocyte Chemotactic Protein 2, Chemokine C-C Motif Ligand 8, CCL8, HC14, Monocyte Chemotactic Protein 2, Small Inducible Cytokine A8 Precursor, SCYA8, SCYA10)
2ug
10ug
10ug
|
Technical Data |
|
M2750-11A |
MCP2, Recombinant, Human (Macrophage/Monocyte Chemotactic Protein 2, Chemokine C-C Motif Ligand 8, CCL8, HC14, Monocyte Chemotactic Protein 2, Small Inducible Cytokine A8 Precursor, SCYA8, SCYA10) |
2ug 10ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: RT |
|
Recombinant Human MCP-2 is a non-glycosylated, polypeptide chain containing 76 amino acids and having a molecular mass of 8904 Dalton. Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Gln-Pro-Asp-Ser-Val. Dimers and Aggregates: 1% as determined by silver-stained SDS-PAGE gel analysis. Biological Activity: MCP-2 is fully biologically active when compared to standard. The specific activity as determined by the ability of MCP-2 to chemoattract human peripheral blood at 10-100ng/ml. Endotoxin: 0.1ng/ug (IEU/ug) of Murine Monocyte Chemotactic Protein-2. Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm. 2. Analysis by RP-HPLC, using a calibrated solution of Human MCP-2 as a Reference Standard. Reconstitution: Reconstitute the lyophilized MCP-2 in sterile 18MO-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions. Storage and Stability: Lyophilized powder may be stored at 4°C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer. |
Source: E. coli Purity: 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Concentration: ~0.1mg/ml Form: Supplied as a lyophilized powder. No additives. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hellier S, Frodsham AJ, Klenerman P, Wright M, Hepatology 2003 Dec;38(6):1468-76 2. Expression of the chemokines, monocyte chemotactic protein (MCP)-1 and MCP-2 in endometrium of normal women and Norplant users, does not support a central role in macrophage infiltration into endometrium. Hampton AL, Rogers PA, Salamonsen LA, J Reprod Immunol 2001 Feb;49(2):115-32 3. Cloning of equine chemokines eotaxin, monocyte chemoattractant protein (MCP)-1, MCP-2 and MCP-4, mRNA expression in tissues and induction by IL-4 in dermal fibroblasts. Benarafa C, Cunningham FM, Horohov DW, Vet Immunol Immunopathol 2000 Oct 31;76(3-4):283-98 4. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Van den Steen PE, Proost P, Van Damme J, Blood 2000 Oct 15;96(8):2673-81 5. Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells. Modulation by corticosteroids and T-helper 2 cytokines. Pype JL, Dupont LJ, Van Coillie E, Demedts MG, Am J Respir Cell Mol Biol 1999 Oct;21(4):528-36 6. Transcriptional control of the human MCP-2 gene promoter by IFN-gamma and IL-1beta in connective tissue cells. Van Coillie E, Van Aelst I, Billiau A, J Leukoc Biol 1999 Sep;66(3):502-11.
|
||